{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MAESTRA 3","nct_id":"NCT07797283","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=maestra-3-nct07797283. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MAESTRA 3","arms":[{"description":"Bevacizumab plus INCB123667 at the protocol defined dose.","label":"Treatment Group A (TGA)","type":"EXPERIMENTAL"},{"description":"Bevacizumab plus matching placebo at the protocol defined dose.","label":"Treatment Group B (TGB)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2034-05-01","type":"ESTIMATED"},"conditions":["Ovarian Cancer"],"enrollment":{"count":590,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"INCB123667","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"Incyte Corporation","official_title":"A Phase 3, Double-Blind, Randomized, Controlled Study of INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1 (MAESTRA 3)","overall_status":"NOT_YET_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-05-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) by BICR","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2026-12-01","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1","url":"https://clinicaltrials.gov/study/NCT07797283"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/maestra-3-nct07797283"}